Department of Gastroenterology, Wuxi People's Hospital Affiliated to Nanjing Medical University, No. 299 Qing Yang Road, Wuxi, 214023, China.
BMC Cancer. 2022 Feb 26;22(1):211. doi: 10.1186/s12885-022-09294-w.
Immunotherapy is a novel hotspot for the treatment of pancreatic adenocarcinoma (PAAD). However, potential biomarkers which could identify the inflamed tumor microenvironment (TME) are urgently required.
In the present study, we measured the levels of B7-H3, B7-H4, and major tumor-infiltrating immune cells (TIICs) using bioinformatics analyses and immunohistochemistry (IHC) staining on PAAD samples represented in the tissue microarray (TMA) format. Statistical analysis and figures exhibition were performed using R 4.1.0, SPSS 26.0, and GraphPad Prism 6.0.
B7-H3 and B7-H4 were up-regulated in PAAD compared with para-tumor tissues, and their expression exhibited no tight correlation in PAAD tissues. B7-H3 and B7-H4 were lowly expressed in well-differentiated PAAD tissues and correlated with poorly differentiated grades. Besides, single B7-H3 or B7-H4 expression exhibited limited prognostic value, but co-deficiency of B7-H3 and B7-H4 predicted a better prognosis in PAAD. Moreover, co-deficiency of B7-H3 and B7-H4 indicated immuno-hot tumors with high CD8 + T cell infiltration.
Overall, combined B7-H3 and B7-H4 expression is a promising stratification strategy to assess prognosis and immunogenicity in PAAD, which could be used as a novel classifier in clinical practice.
免疫疗法是治疗胰腺导管腺癌(PAAD)的新热点。然而,迫切需要能够识别炎症肿瘤微环境(TME)的潜在生物标志物。
在本研究中,我们使用生物信息学分析和免疫组织化学(IHC)染色测量了组织微阵列(TMA)格式的 PAAD 样本中 B7-H3、B7-H4 和主要肿瘤浸润免疫细胞(TIIC)的水平。使用 R 4.1.0、SPSS 26.0 和 GraphPad Prism 6.0 进行统计分析和图形展示。
与癌旁组织相比,B7-H3 和 B7-H4 在 PAAD 中上调,并且它们在 PAAD 组织中的表达没有紧密相关性。B7-H3 和 B7-H4 在分化良好的 PAAD 组织中低表达,并与低分化程度相关。此外,单一的 B7-H3 或 B7-H4 表达显示出有限的预后价值,但 B7-H3 和 B7-H4 的共同缺失预测了 PAAD 更好的预后。此外,B7-H3 和 B7-H4 的共同缺失表明免疫热肿瘤具有高 CD8+T 细胞浸润。
总体而言,联合 B7-H3 和 B7-H4 的表达是评估 PAAD 预后和免疫原性的一种很有前途的分层策略,可作为临床实践中的新型分类器。